Symbiotec Pharmalab - News

NSE: SYMBIOTEC | BSE: 544889

₹1,164.20

₹-33.30 (-2.78%)

As on 23-Oct-2026IST

Market cap

₹7,479 Cr

Revenue (TTM)

₹869 Cr

P/E Ratio

68.1

P/B Ratio

5

Div. Yield

0 %

Quarterly Updates

2026

Announcements

View Announcements

Recent

Important

Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.

16-Oct-2026

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

05-Oct-2026

Symbiotec''s Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agreement With A Leading Global Pharmaceutical Company For Dual Chamber Vial Products In The U.S.

30-Sep-2026

Closure of Trading Window

29-Sep-2026

Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report ("EIR") From U.S. FDA For Its Manufacturing Facility In Pithampur ('SEZ') With VAI Classification

29-Sep-2026

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

28-Sep-2026

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

22-Sep-2026

Announcement under Regulation 30 (LODR)-Newspaper Publication

22-Sep-2026

Announcement under Regulation 30 (LODR)-Press Release / Media Release

21-Sep-2026

Announcement under Regulation 30 (LODR)-Investor Presentation

21-Sep-2026